Signed in · PRO
Ashland / Full history

Guidance history, every release

Ashland (ASH) · 8 releases, Nov 6, 2024 to Jul 28, 2026 · rows are metrics, columns are releases
Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing
MetricNov 6, 2024
FY24 Q4
Jan 28, 2025
FY25 Q1
Apr 30, 2025
FY25 Q2
Jul 29, 2025
FY25 Q3
Nov 4, 2025
FY25 Q4
Feb 2, 2026
FY26 Q1
Apr 28, 2026
FY26 Q2
Jul 28, 2026
FY26 Q3
For FY2026
Adjusted Diluted Earnings Per Share Excluding Intangibles Amortization—————New“double digit plus growth”Lowered“mid-to-high single-digit growth”Lowered“low-to-mid single-digit growth”
Adjusted Diluted Earnings Per Share Excluding Intangibles Amortization Expense growth————New“double-digit-plus”———
Adjusted EBITDA————New“$400 million to $430 million”Narrowed“$400 million to $420 million”Lowered“$385 million to $400 million”Reiterated“$385 to $400 million”
Adjusted EPS outlook———————New“low-to-mid-single digit growth from mid-to-high-single digit growth”
Calvert City production unit impact on adjusted EBITDA————New“roughly $10 million”———
Accrual of performance-based compensation at target levels and merit increases————New“approximately $20 million”———
Capital expenditures————New“approximately $100 million”Reiterated“approximately $100 million”Reiterated“approximately $100 million”Lowered“approximately $~90 million”
Cost savings under the $90 million dollar program—————New“approximately $30 million”——
Execute strategic priority - cost savings under the $90 million program————New“approximately $30 million”———
Globalize strategic priority - incremental sales————New“$20 million”———
Incremental investments in research and development to advance disruptive platform opportunities————New“about $4 million”———
Innovate strategic priority - incremental innovation driven sales————New“$15 million”———
Manufacturing network optimization full program————New“$60 million”———
Manufacturing network optimization incremental cost savings————New“$50 million to $55 million”———
Manufacturing optimization program cost savings—————New“approximately $30 million in cost savings under the $90 million dollar program”——
Manufacturing optimization program fiscal 2026 savings expectations reduction——————New“approximately $10 to $12 million”—
Ongoing Free Cash Flow Conversion————New“approximately 50 percent of Adjusted EBITDA”Reiterated“approximately 50 percent of Adjusted EBITDA”Reiterated“approximately 50 percent of Adjusted EBITDA”Revised“greater than 50 percent of Adjusted EBITDA”
Restructuring plan realizationNew“50 percent”———————
Sales————New“$1,835 million to $1,905 million”Reiterated“$1,835 million to $1,905 million”Narrowed“$1,835 to $1,870 million”Reiterated“$1,835 to $1,870 million”
Sales organic growth————New“approximately one to five percent”———
Temporary impacts from the Calvert City startup delay and recent weather-related disruptions—————New“approximately $11 million”——
For FY2025
Adjusted EBITDA———New“$400 million to $410 million”————
Adjusted EBITDANew“$430 million to $470 million”Reiterated“$430 million to $470 million”Lowered“$400 million to $420 million”—————
Avoca year-over-year EBITDA erosionNew“($15) million”———————
Reduced earnings and stranded costs from nutraceuticals sale and other portfolio optimization actionsNew“($30) million”———————
$30 million restructuring plan realizationNew“50 percent realization in fiscal year 2025 and 50 percent in fiscal year 2026”———————
$30 million restructuring program savings———New“approximately $7.5 million”————
Estimated tariff impact——New“$3 to $5 million for the second half”—————
Estimated tariff impact, annually after mitigation actions——New“$5 to $7 million annually after mitigation actions”—————
Fiscal 2025 sales———New“approximately $1.825 billion to $1.850 billion”————
Full fiscal year sales—New“$1.90 billion to $2.05 billion”Lowered“$1.825 billion to $1.9 billion”—————
Improved first-half absorption when compared to inventory actions in fiscal 2024New“+$45 million”———————
Manufacturing optimization restructuring plan pre-tax savings (HEC and VP&D)New“$5 million”———————
Negative price carryover from fiscal year 2024New“($20) million”———————
Organic sales volume growth——New“flattish organic sales volume growth”—————
Realized cost reduction actionsNew“+$20 million”———————
Restructuring plan realizationNew“50 percent”———————
Restructuring program savings———New“approximately $7.5 million”————
SalesNew“$1.90 billion to $2.05 billion”———————
Variable incentive resetNew“($10) million”———————
No period stated
Incremental cost savings from manufacturing network optimization————New“$50 million to $55 million”———
Manufacturing network optimization full program savings————New“the full $60 million program remains achievable as market conditions improve”———
Manufacturing optimization plan——New“$60 million manufacturing optimization plans”—————
Manufacturing optimization restructuring plan pre-tax savings (HEC and VP&D)New“$60 million once fully achieved”———————
Manufacturing optimization restructuring plan pre-tax savings (once fully achieved)New“$60 million”———————
Restructuring planNew“$30 million”———————
Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.